pylori)
are proton pump inhibitor, amoxacillin, and clarithromycin. Considering the convenience of the patient, it is more helpful to take the drugs at once postprandial compared to take the drugs dividing by preprandial and postprandial. But, proton pump inhibitor is more effective when taking preprandial. The aim of this study was to determine the difference in eradication rates according to the method of treatment of H.pylori. Methods: Between January 2008 and December 2012, a total 160 patients with positive by rapid urease test at our hospital were reviewed, retrospectively. We divided into two groups in accordance with the prescribed methods of H.pylori. PLX-4720 supplier One group of people were prescribed the drugs at once postprandial (group A). Another group of people were prescribed proton pump inhibitor at preprandial with amoxicillin and clarithromycin at postprandial (group B). After 4 weeks, urea breath test was performed to validate eradication of H.pylori. Results: The rate of eradication of group A was 75% (60/80) and the rate of eradication
of group B was 72.5% (58/80). There was no GDC-0973 nmr significant difference between two groups (p = 0.719). Conclusion: To take the regimens for treatment of H.pylori at once postprandial or dividing by preprandial and postprandial was no significant difference in eradication rates of H.pylori. Therefore, to prescribe at once postprandial
maybe the better way, considering the convenience of the patient. Key Word(s): 1. PPI; 2. Pre-prandial; 3. H.Pyolori; Group A Group B p-value Male: Female ratio 50:30 59:21 0.127 Mean age 51.45 53.34 0.334 Eradication rate of H.pylori 75% (60/80) 72.5% (58/80) 0.719 Presenting Author: KYU KEUN KANG Additional Authors: DONG HO LEE, DONG HYUN OH, NAYOUNG KIM, YOUNG SOO PARK, CHEOL MIN SHIN, HYUK YOON, JIN HYEOK HWANG Corresponding Author: DONG HO LEE Affiliations: Thalidomide Seoul National University Bundang Hospital Objective: There was a controversy the efficacy of eradication with moxifloxacin based triple therapy as second line treatment for Helicobacter pylori infection. And most of published papers focused on patients failed to treat with standard triple therapy. So, we investigated the efficacy of moxifloxacin as second line therapy and the eradication rates of that according to previous first-line regimen. Methods: A total of 298 patients who were failed to eradicate with first line treatment received 14 days moxifloxacin containing triple therapy (moxifloxacin 400 mg q.d, amoxicillin 1000 mg b.i.d, rabeprazole 20 mg b.i.d). As first line treatment, they were prescribed 7day-standard triple therapy (n = 184), 7day-bisthmus containing quadruple therapy (n = 29), 7day-concomitant therapy (n = 39) and 14day-sequential therapy (n = 46).